Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Eur J Med Res. 2023 Nov 28;28(1):546. doi: 10.1186/s40001-023-01534-4.
Tumor size plays an important role in the staging and treatment of thyroid carcinoma. A tumor with a maximum diameter of 1 cm or less is referred to as microcarcinoma. It is unclear if the clinicopathological characteristics and prognosis of medullary thyroid microcarcinoma (≤ 1 cm; MTMC) and macrocarcinoma (> 1 cm) differ. The present study aims to clarify the clinical features and prognosis of patients with MTMC.
The patients with medullary thyroid carcinoma underwent radical operation at our hospital between December 2000 and January 2022 were retrospectively studied. A database was established for this study. Patients with MTMC and macrocarcinoma were grouped for comparison. The clinicopathological characteristics of the two groups were compared by χ test, Fisher's exact test, t-test, and Mann-Whitney U test. Cumulative survival rates were presented by the Kaplan-Meier curves and compared using the log-rank test.
A total of 198 patients were included. Of them, 56 and 142 with MTMC and macrocarcinoma, respectively. Few patients in the MTMC group had lateral lymph node metastasis. One hundred and seventy-eight (89.9%) patients were followed up, with a median follow-up period of 61 (35, 105) months. The disease-free survival rate was significantly higher in the MTMC group (log-rank test, p = 0.032); however, there was no significant difference in the overall survival rate between the two groups (log-rank test, p = 0.083).
Patients with MTMC have a lower risk of lateral lymph node metastasis and better disease-free survival than those with macrocarcinoma. However, there was no significant difference in the overall survival rate of both groups. MTMC should be treated in the same manner as macrocarcinoma.
肿瘤大小在甲状腺癌的分期和治疗中起着重要作用。最大直径为 1cm 或以下的肿瘤称为微癌。目前尚不清楚甲状腺髓样癌微癌(≤1cm;MTMC)和大癌(>1cm)的临床病理特征和预后是否不同。本研究旨在阐明 MTMC 患者的临床特征和预后。
回顾性分析 2000 年 12 月至 2022 年 1 月期间在我院行根治性手术的甲状腺髓样癌患者。为此研究建立了一个数据库。将 MTMC 和大癌患者分为两组进行比较。通过卡方检验、Fisher 确切检验、t 检验和 Mann-Whitney U 检验比较两组的临床病理特征。采用 Kaplan-Meier 曲线表示累积生存率,并通过对数秩检验进行比较。
共纳入 198 例患者,其中 MTMC 组 56 例,大癌组 142 例。MTMC 组患者中,侧方淋巴结转移者较少。178 例(89.9%)患者获得随访,中位随访时间为 61(35,105)个月。MTMC 组无病生存率显著高于大癌组(对数秩检验,p=0.032);但两组总生存率无显著差异(对数秩检验,p=0.083)。
MTMC 患者侧方淋巴结转移风险较低,无病生存率优于大癌患者。然而,两组的总生存率无显著差异。MTMC 应与大癌一样治疗。